Cargando…

Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis

PURPOSE: Severity of Graves’ orbitopathy (GO) shows wide individual differences. For optimal treatment, it is important to be able to predict the natural course of the disease as accurate as possible to counteract with anti-inflammatory and surgical treatment. Therefore, we aimed to further elucidat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oeverhaus, Michael, Winkler, Luisa, Stähr, Kerstin, Daser, Anke, Bechrakis, Nikolaos, Stöhr, Mareile, Chen, Ying, Eckstein, Anja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110835/ https://www.ncbi.nlm.nih.gov/pubmed/37082130 http://dx.doi.org/10.3389/fendo.2023.1160172

Ejemplares similares

Proposing a surgical algorithm for graduated orbital decompression in patients with Graves’ orbitopathy
por: Stähr, Kerstin, et al.
Publicado: (2021)

Graves’ orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model
por: Schlüter, Anke, et al.
Publicado: (2018)

18 F-FDG-PET/MRI in patients with Graves’ orbitopathy.
por: Weber, Manuel, et al.
Publicado: (2021)

Influence of orbital morphology on proptosis reduction and ocular motility after decompression surgery in patients with Graves’ orbitopathy
por: Oeverhaus, Michael, et al.
Publicado: (2019)

First Evaluation of a Retinal Imaging Laser Eyewear System Based Low Vision Aid
por: Stöhr, Mareile, et al.
Publicado: (2020)

Incidence of A pattern strabismus after inferior rectus recession in patients with Graves' orbitopathy: A retrospective multicentre study
por: Jellema, Hinke Marijke, et al.
Publicado: (2022)

Modulating gut microbiota in a mouse model of Graves’ orbitopathy and its impact on induced disease
por: Moshkelgosha, Sajad, et al.
Publicado: (2021)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease
por: Gulbins, Anne, et al.
Publicado: (2023)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

OR26-03 Treatment With Linsitinib, An IGF-1 Receptor Inhibitor, Prevents Disease Development And Progression In An Experimental Model Of Thyroid Eye Disease
por: Gulbins, Anne, et al.
Publicado: (2023)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Markers of Inflammation and Fibrosis in the Orbital Fat/Connective Tissue of Patients with Graves' Orbitopathy: Clinical Implications
por: Pawlowski, Przemyslaw, et al.
Publicado: (2014)

Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves’ disease and orbitopathy
por: Zhang, Lei, et al.
Publicado: (2018)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease
por: Gulbins, Anne, et al.
Publicado: (2023)

Endoscopic intranasal orbital decompression in the course of Graves’ orbitopathy
por: Krzeski, Antoni, et al.
Publicado: (2013)

Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2014)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
por: Boddu, Neeraja, et al.
Publicado: (2017)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

Factors associated with severity of orbitopathy in patients with Graves' disease
por: Nabi, Tauseef, et al.
Publicado: (2020)

Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
por: Bednarczuk, Tomasz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_muin1nut55or49nk1njso77fkn